VRC-MARDNA025-00-VP

VRC-MARDNA025-00-VP is a DNA plasmid vaccine developed as a prophylactic vaccine against Marburg virus disease. The vaccine encodes the glycoprotein of the Marburg virus (specifically, the Angola strain), aiming to induce an immune response that protects against infection. It does not contain live or inactivated virus but instead uses genetic material to prompt the body to produce viral proteins and generate immunity. The primary indication is for prevention of Marburg virus disease, a severe hemorrhagic fever caused by Marburg virus, which is closely related to Ebola. Phase 1 clinical trials have demonstrated safety and immunogenicity in healthy adults, with most participants developing antibody responses after vaccination[1][3][5][6][7][9].